← Back to Home

In Vivo CAR-T Faces Another Tumor Challenge: Azalea Mouse Study Shows Signs of Sustained Control

After a single dose, some mice continued to control tumors when rechallenged with leukemia cells about 60 days later. New data also extend to dual targeting and solid tumors, but key gaps remain before efficacy and safety in humans can be established.

By SURL BioNews

Giving immune cells the ability to recognize cancer cells directly inside the body is only the first step; whether this cancer-fighting force can persist and respond to another attack is the longer-term test. New animal data released by Azalea Therapeutics on November 6 show that, in some groups of humanized mice, its in vivo CAR-T platform not only cleared leukemia but also maintained control after another inoculation with tumor cells, offering new clues about whether its effects can persist.

According to the company announcement, the study used a single intravenous injection combining two vectors to generate CAR-T cells in humanized mice and cleared CD19-expressing NALM6 leukemia at active doses. Some treatment groups underwent a second tumor challenge approximately 60 days after the initial dose and maintained tumor control without additional dosing. These data are included in abstract No. 950 at the Society for Immunotherapy of Cancer annual meeting, SITC 2026, scheduled for presentation on November 7; the announcement did not specify the number of animals in each group or the full duration of follow-up after rechallenge.

The platform centers on two vectors working together: a T-cell-targeted enveloped delivery vehicle (EDV) delivers transiently active CRISPR-Cas9 complexes, while a T-cell-tropic adeno-associated virus (AAV) carries the CAR gene. The study design inserts a promoterless CAR gene into the TRAC locus, placing expression under the cell’s existing regulatory machinery to carry out the modification in vivo.

The new data also tested more complex designs. CAR-T cells that recognize both CD19 and CD20 showed activity against leukemia cells with heterogeneous antigen expression, providing preliminary support for reducing tumor escape; in a mesothelin-expressing solid tumor model, adding a function-enhancing peptide further improved control. However, the announcement did not provide complete data sufficient to compare the magnitude of the effects across the different designs.

The site of gene insertion is also important for further development. The company analyzed human cells in the spleens of humanized mice and found that 99% of sequencing reads that passed filtering mapped to the intended TRAC site. This proportion describes the distribution of the reads analyzed; it cannot be interpreted as meaning that 99% of T cells were successfully modified, nor is it sufficient on its own to establish the absence of unintended integration or other gene-editing risks.

Background

Conventional CAR-T therapy requires cells to be collected, modified and expanded outside the body, and then infused back into the patient. Writing cancer-fighting instructions directly into cells in vivo aims to reduce this individualized manufacturing process; the dual-vector strategy already had a foundation in earlier mouse studies. The main addition this time is extending testing to repeat tumor challenges and designs involving dual targeting and functional enhancement, but there is no clinical evidence yet that this can actually shorten the treatment process or lower costs.

The currently verifiable GlobeNewswire announcement and BioSpace version originate from the same company press release and do not constitute two independent validations. Humanized mice also cannot fully reproduce the human immune and tumor environments, and the results of repeat inoculation with tumor cells cannot be directly translated into patients’ risk of relapse. These findings support further research; advancing to humans will still require clarification of the scope of delivery, unintended genetic changes, immune responses, and long-term cell behavior.

References

  1. Azalea Therapeutics / GlobeNewswire
  2. BioSpace (Azalea Therapeutics syndicated press release)